Although the immunomodulator cyclosporin A (CsA, 1) 1 has engendered dramatic progress in organ transplantation, recurrent clinical complications have stimulated an ongoing search for more potent and less toxic agents. The discovery of FK506 (2) 2 and the reinvestigation of rapamycin (3) 3 and demethoxyrapamycin (4) 4 heralded major advances in immunosuppressant research; not only are these natural products more potent than CsA, but they also selectively inhibit two distinct steps in the immune response. CsA and FK506, bound to immunophilins cyclophilin A and FKBP, respectively, prevent cells from entering the G 1 phase of the cell cycle, whereas the rapamycin-FKBP complex blocks progression into the S phase. The molecular biology, immunology and pharmacology of CsA, FK506, and rapamycin have been recently reviewed. 5 Discodermolide (5), first described in 1990, 6 displays immunomodulating activity intermediate between those of CsA and FK506. 7 In Burkitt lymphoma cells, discodermolide causes marked microtubule bundling, thereby arresting cellular development at the G 2 /M transition. 8 This mode of action is similar to that of Taxol, albeit its binding affinity is much higher than Taxol. As such, (+)-discodermolide could prove to be an effective therapeutic agent for the treatment of cancer. 8 The complex architecture and therapeutic importance of these nonpeptidal immunomodulators have attracted considerable interest among synthetic chemists, culmi- † This account is dedicated to